Quality-of-life differences among various populations of localized prostate cancer patients: 2001
- PMID: 12084195
- DOI: 10.1007/BF03200419
Quality-of-life differences among various populations of localized prostate cancer patients: 2001
Abstract
An increasing number of studies are being published on the impact of localized prostate cancer on patient quality of life. Research suggests that the majority of patients diagnosed with prostate cancer return to pretreatment levels of general quality of life within 1 year after treatment. However, sexual, urinary, and bowel symptoms continue to be an issue for many patients beyond 1 year post-treatment. Focusing on psychologic impacts and social functioning, in addition to physical symptoms, may provide useful avenues for improving patient quality of life. We also discuss emerging evidence of racial and/or ethnic disparities in prostate cancer-related quality of life, the role of social networks and support in recovery and adjustment, as well as the impact of cancer recurrence.
Similar articles
-
The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer.J Urol. 2001 Nov;166(5):1804-10. J Urol. 2001. PMID: 11586228
-
Prospective longitudinal comparative study of health-related quality of life in patients undergoing invasive treatments for localized prostate cancer.J Endourol. 2005 Apr;19(3):318-26. doi: 10.1089/end.2005.19.318. J Endourol. 2005. PMID: 15865521
-
Impact of age on quality-of-life outcomes after treatment for localized prostate cancer.Eur Urol. 2015 Sep;68(3):480-6. doi: 10.1016/j.eururo.2015.01.008. Epub 2015 Feb 2. Eur Urol. 2015. PMID: 25656807
-
Quality of life outcomes following treatment for localized prostate cancer: is there a clear winner?Curr Opin Urol. 2009 May;19(3):303-8. doi: 10.1097/MOU.0b013e328329eb00. Curr Opin Urol. 2009. PMID: 19300266 Review.
-
Prostate specific antigen only progression of prostate cancer.J Urol. 2000 Jun;163(6):1632-42. J Urol. 2000. PMID: 10799151 Review.
Cited by
-
Quality of life and economic considerations in the management of prostate cancer.Pharmacoeconomics. 2003;21(8):527-41. doi: 10.2165/00019053-200321080-00001. Pharmacoeconomics. 2003. PMID: 12751912 Review.
-
Integration of Patient Reported Outcomes in Drug Development in Genitourinary Cancers.Curr Oncol Rep. 2020 Feb 8;22(3):21. doi: 10.1007/s11912-020-0890-3. Curr Oncol Rep. 2020. PMID: 32036478 Review.
Publication types
MeSH terms
LinkOut - more resources
Medical